☆ 4.8 Article

Dabigatran Etexilate A New Oral Thrombin Inhibitor

CIRCULATION (2011)

Get Full Text
Add to Collection

Journal

CIRCULATION
Volume 123, Issue 13, Pages 1436-1450

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/CIRCULATIONAHA.110.004424

Keywords

anticoagulants; atrial fibrillation; dabigatran etexilate; direct thrombin inhibitor; stroke

Categories

Cardiac & Cardiovascular Systems Peripheral Vascular Disease

Funding

  1. Astra-Zeneca
  2. Bayer
  3. Boehringer-Ingelheim
  4. Bristol-Myers-Squibb
  5. Daiichi-Sankyo
  6. Eli-Lilly
  7. Glaxo-Smith-Kline
  8. Johnson Johnson
  9. Portola
  10. Sanofi-Aventis

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.